EUCTR2004-001467-22-IT进行中（未招募）不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCERlocally recurrent or metastatic BCMedDRA version: 7.1Level: LLYClassification code 10055113EUCTR2005-003773-25-BEPFIZER s.a.128
进行中（未招募）
不适用
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES - NDon-Small Cell Lung Cancer NSCLC patients with brain metastasesMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-004451-38-ITPFIZER60
进行中（未招募）
1 期
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCERHistologically proven NSCLC (Stage IV or recurrent disease or locally advanced [Stage IIIB]) that is not amenable to surgery, radiation, or combined modality therapy with curative intentEUCTR2004-001467-22-ESPfizer S.A.60
进行中（未招募）
1 期
A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASESon-Small Cell Lung Cancer (NSCLC) patients with brain metastasesMedDRA version: 8.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-004451-38-FRPfizer Inc. - 235 East 42nd Street - New York - 1001760
进行中（未招募）
不适用
A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCERRecurrent or metastatic non-nasopharyngeal head and neck cancerEUCTR2005-004939-22-GRHellenic Cooperative Oncology Group (HeCOG)